NDLI: The effect of dapagliflozin treatment on epicardial adipose tissue volume

Content Provider	Springer Nature : BioMed Central
Author	Sato, Takao Aizawa, Yoshifusa Yuasa, Sho Kishi, Shohei Fuse, Koichi Fujita, Satoshi Ikeda, Yoshio Kitazawa, Hitoshi Takahashi, Minoru Sato, Masahito Okabe, Masaaki
Abstract	Background Glycosuria produced by sodium–glucose co-transporter-2 (SGLT-2) inhibitors is associated with weight loss. SGLT-2 inhibitors reportedly might reduce the occurrence of cardiovascular events. Epicardial adipose tissue (EAT) is a pathogenic fat depot that may be associated with coronary atherosclerosis. The present study evaluated the relationship between an SGLT-2 inhibitor (dapagliflozin) and EAT volume. Methods In 40 diabetes mellitus patients with coronary artery disease (10 women and 30 men; mean age of all 40 patients was 67.2 ± 5.4 years), EAT volume was compared prospectively between the dapagliflozin treatment group (DG; n = 20) and conventional treatment group (CTG; n = 20) during a 6-month period. EAT was defined as any pixel that had computed tomography attenuation of − 150 to − 30 Hounsfield units within the pericardial sac. Metabolic parameters, including HbA1c, tumor necrotic factor-α (TNF-α), and plasminogen activator inhibitor-1 (PAI-1) levels, were measured at both baseline and 6-months thereafter. Results There were no significant differences at baseline of EAT volume and HbA1c, PAI-1, and TNF-α levels between the two treatment groups. After a 6-month follow-up, the change in HbA1c levels in the DG decreased significantly from 7.2 to 6.8%, while body weight decreased significantly in the DG compared with the CTG (− 2.9 ± 3.4 vs. 0.2 ± 2.4 kg, p = 0.01). At the 6-month follow-up, serum PAI-1 levels tended to decline in the DG. In addition, the change in the TNF-α level in the DG was significantly greater than that in the CTG (− 0.5 ± 0.7 vs. 0.03 ± 0.3 pg/ml, p = 0.03). Furthermore, EAT volume significantly decreased in the DG at the 6-month follow-up compared with the CTG (− 16.4 ± 8.3 vs. 4.7 ± 8.8 cm3, p = 0.01). Not only the changes in the EAT volume and body weight, but also those in the EAT volume and TNF-α level, showed significantly positive correlation. Conclusion Treatment with dapagliflozin might improve systemic metabolic parameters and decrease the EAT volume in diabetes mellitus patients, possibly contributing to risk reduction in cardiovascular events.
Related Links	https://cardiab.biomedcentral.com/counter/pdf/10.1186/s12933-017-0658-8.pdf
Ending Page	9
Page Count	9
Starting Page	1
File Format	HTM / HTML
ISSN	14752840
DOI	10.1186/s12933-017-0658-8
Journal	Cardiovascular Diabetology
Issue Number	1
Volume Number	17
Language	English
Publisher	BioMed Central
Publisher Date	2018-01-04
Access Restriction	Open
Subject Keyword	Diabetes Angiology Cardiology SGLT-2 inhibitor Epicardial adipose tissue Diabetes mellitus
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine Internal Medicine Endocrinology, Diabetes and Metabolism
Journal Impact Factor	8.5/2023
5-Year Journal Impact Factor	8.9/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers

SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives

Epicardial adipose tissue and severe Coronavirus Disease 19

Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes

Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis

The effect of dapagliflozin treatment on epicardial adipose tissue volume

Similar Documents

Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers

SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives

Epicardial adipose tissue and severe Coronavirus Disease 19

Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes

Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis

The effect of dapagliflozin treatment on epicardial adipose tissue volume